The world’s changing geopolitical situation has disrupted global supply chains; therefore, new alliances have been formed. It is now obvious that the drivers of future economic and strategic leadership are shifting. Leadership used to be defined by military might or industrial capacity. In the future, leadership will be driven by technological and manufacturing capabilities, particularly in artificial intelligence (AI), biotechnology, and renewable energy. It is critical to be self-sufficient in these sectors so that no other country uses them as a bargaining tool.
India has made significant progress in pursuing both clean energy and AI. However, we have not yet laid enough emphasis on biotechnology, in particular regenerative health care. It hasn’t been utilised as a potential competitive advantage. Unlocking this field can spur further innovation, but also create significant health and economic outcomes for our large population.
From managing symptoms to treating the underlying issue
India faces a massive burden from chronic diseases like Diabetes, Arthritis, Chronic Kidney Disease (CKD), non-alcoholic fatty liver disease and Heart Disease. Conventional medicine only manages these symptoms, such as daily insulin, thrice-weekly dialysis, or lifelong cardiac meds, etc. Regenerative medicine, on the other hand, aims to restore body function.
From a public health spending and economic perspective, regenerative healthcare changes the perspective and outcomes from merely "managing" disease to "curing" it. For India, with its 1.4 billion population, this shift can significantly reduce the long-term financial burden on both the Government and the common citizen.
Regenerative healthcare provides a new treatment approach by attempting to restore function through treatments such as stem cell therapy, platelet-rich plasma (PRP), or tissue engineering, rather than just managing symptoms.
What is Regenerative Healthcare
Regenerative healthcare, in simple terms, is repairing or replacing damaged tissues, cells or organs to restore their normal function. The main components of Regenerative Healthcare are:
-
Autologous procedures: These are same-day procedures that use the patient's own cells or tissues and, with minimal manipulation, are reinjected back into the patient’s joint or tissue.
-
Cell therapies (stem cell therapy): These are autologous or allogenic (not from the same patient) therapies where specific cells are concentrated or multiplied significantly. These are typically referred to as more than minimally manipulated cells or tissues.
-
Tissue engineering: Tissue engineering combines scaffolds, cells and/or active biological material to create functional tissue so as to replace damaged ones. A good example of this is skin grafts.
-
Gene Therapy: In Gene Therapy, one typically introduces or removers or alters genetic material within the patient’s cells to treat or prevent diseases.
The Promise of Regenerative Healthcare
-
Clinical relevance: The need for getting a cure rather than just symptom management and relief, in patients with osteoarthritis, diabetes, and cardiovascular disease, has created a large opportunity for regenerative therapies that have the potential to modify disease through the use of autologous cell concentrates, platelet-rich plasma, and advanced tissue scaffolding/engineering.
-
Economic opportunity: The healthcare market in India is expected to be around $650 billion by 2025. Over the coming years, regenerative medicine is going to be a significant contributor to this market. At the same time, it also provides long-term reduction of treatment costs and creates new medical technology and biotechnology infrastructures.
-
Global positioning: The diverse makeup of India’s patient population, coupled with its many skilled clinicians and engineers, low-cost manufacturing capability, and affordability, will allow India to become the preferred location for the manufacturing and innovation of regenerative medicine products.
Challenges of scaling up
1. Regulatory Ambiguity
Different governmental healthcare regulatory bodies seem to have overlapping jurisdiction, causing confusion amongst manufacturers and marketing companies on the exact regulatory framework to be followed. For example, Autologous therapies (like minimally manipulated cell-based or tissue-based procedures) often risk falling into a grey zone with drugs/devices/single-sitting procedures. These regulations fit well with allogenic, more than minimally manipulated, cell/tissue therapies.
2. Barriers to Implementing Regenerative Therapies at scale
The introduction of regenerative medicine in India has faced numerous barriers at both the systemic and structural levels. There is no standardisation in clinical guidelines, which results in variable patient outcomes. Moreover, there is limited training for orthopaedic surgeons and other clinicians, preventing them from developing sufficient clinical confidence in regenerative protocols.
Both of these problems result in a weak reimbursement pathway for regenerative therapies. Patients currently bear the entire cost of their treatment, as insurers rarely provide reimbursement for these procedures. Low adoption inhibits scaling up, which results in very high up-front costs of devices and consumables for both hospitals and small clinics, resulting in less incentive, particularly for smaller hospitals and clinics to perform regenerative procedures.
Additionally, there are only a limited number of dedicated centres of excellence in regenerative medicine in India, therefore creating barriers to both patient access and the opportunity to conduct advanced research and training. All of these factors together create an environment where the use of regenerative medicine for the treatment of patients is not widespread, despite much scientific evidence supporting the efficacy and safety of these therapies (this includes randomised controlled trials, prospective studies and cohort studies, among many other types of studies).
3. Legal & Ethical Concerns
Given the regulatory overlap between different governmental bodies and, therefore, the perception of these treatments being ‘experimental’, there are significant legal and ethical issues to be addressed.
-
Litigation risks around unproven therapies marketed directly to patients and the claims made by doctors about the effects of these procedures.
-
Ethical concerns about stem cell misuse and unregulated clinics.
-
Need for stronger patient education and informed consent frameworks.
-
Need for doctors doing these treatments to undergo relevant certification
A Roadmap for Scale – Bridging the Policy Gap
A coordinated and forward-looking approach is required to unlock the full potential of Regenerative Healthcare in India.
1. Regulatory Reform
-
Establish a dedicated regenerative medicine approval board within CDSCO/ICMR. It should be a single window approval system.
-
The Regenerative Medicine approval board will provide approval for all types of things related to Regenerative Medicine, from procedures to devices to clinical standardisation protocols.
-
Create fast-track approval pathways for autologous and minimally manipulated therapies.
-
Introduce conditional approvals with mandatory post-market surveillance.
2. Developing a clinical ecosystem
-
Developing centers of excellence in various specialities such as orthopedics, cardiology, gynaecology, neurology and endocrinology is the need of the hour. These should have Government as well as private participation.
-
Propagating Regenerative Medicine through medical curricula and CME programs.
-
Standardising clinical and procedural protocols endorsed by various medical associations.
3. Legal & Ethical Clarity
-
Creating a consistent framework for patient consent with clear disclosure of risks and benefits.
-
Monitor newer evidence on a routine basis and update recommendations in a timely fashion
4. Financing & Insurance coverage
-
Introduce insurance pilots covering regenerative procedures for osteoarthritis and diabetes. Regenerative Healthcare, whether an autologous or allogenic procedure, removes the need for lengthy hospitalisation. Some of these procedures can be done in outpatient settings, thereby reducing the cost of treatment and insurance companies need to encourage reimbursement of daycare procedures.
-
Provide tax incentives and grants for startups developing regenerative devices.
-
Encourage private equity/venture capital and CSR investments in regenerative healthcare.
A Collaborative Path Forward
In order to scale, a collaborative effort among all stakeholders across the entire value chain will be necessary. Policymakers should provide appropriate regulatory clarity, incentives, and protections so that various stakeholders gain confidence. Clinicians need to practice and adopt evidence-based regenerative protocols. They should also take the lead in patient education so that patients accept this medical treatment option. Businesses should focus their investment on research, manufacturing, and training to ensure the accessibility and quality of their products.
Educational and Research Institutions play an important role in advancing translational research and validating clinical outcomes. Additionally, Investors must also provide funding avenues for startups so as to grow exponentially.
Conclusion: The Shift from Treatment to Cure
By using regenerative medicine as a means to solve an underlying problem, there will be fewer surgeries and hospitalisations, and fewer drugs will be needed to treat chronic diseases. Whilst India is well positioned to become a major player in the global regenerative medicine sector, a strong policy and regulatory fillip will do wonders for the industry. This will result in not only cost-effective healthcare for millions but also in reducing the financial burden on families and the healthcare system.
